Overview

Study to Evaluate the Feasibility of [18F]Florbetapir PET for Assessment in MS Patients

Status:
Completed
Trial end date:
2013-11-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the feasibility of [18F]Florbetapir positron emission tomography (PET) for assessment of demyelination in the patients with relapsing remitting multiple sclerosis.
Phase:
Phase 4
Details
Lead Sponsor:
Institute for Neurodegenerative Disorders
Collaborator:
Biogen